Clinical trial
Preop Chemoradiation Resectable Pancreas
NCT00336648 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00336648 |
|---|---|
| Title | Preop Chemoradiation Resectable Pancreas |
| Official title | A Phase II Pilot Study of Preoperative Gemcitabine and Bevacizumab-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreas |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Neoplasms |
| Intervention type | Drug, Procedure |
| Interventions | Avastin (Bevacizumab), Gemcitabine, Radiation Therapy |
| Enrollment | 11 |
| Start date | Jun 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Jul 1, 2008 |
| First posted | Jun 14, 2006 |
| Last update posted | Jul 30, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: